ISIS & ASCO APO & CRP: Blockbuster Alphabet Soup for ISIS? Among its broad and deep R&D pipeline, ISIS has two potential home run compounds with important Phase II clinical data due by mid-year â each addressing multiple blockbuster drug markets. In our view, a successful result from either candidate is likely to establish ISISâ[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.